A new study indicates that triggering receptor expressed on myeloid cells 2 (TREM2) is an important phagocytic immunomodulator in mouse and human gliomas. TREM2 was found to regulate phagocytosis via the spleen tyrosine kinase pathway and, unlike in other cancers, TREM2 expression was not associated with immunosuppressive pathways. TREM2⁺ myeloid cells showed increased tumour uptake compared with TREM2^– cells, which suggests that TREM2-enhancing strategies could be a therapeutic approach for gliomas.

中文翻译：

---

TREM2 介导胶质母细胞瘤的吞噬作用

一项新的研究表明，骨髓细胞表达的触发受体 2 (TREM2) 是小鼠和人类神经胶质瘤中重要的吞噬细胞免疫调节剂。人们发现 TREM2 通过脾酪氨酸激酶途径调节吞噬作用，并且与其他癌症不同，TREM2表达与免疫抑制途径无关。与 TREM2 ^-细胞相比， TREM2 ⁺骨髓细胞显示肿瘤摄取增加，这表明 TREM2 增强策略可能成为神经胶质瘤的治疗方法。